Orchestra BioMed (Nasdaq:OBIO) today announced the first patient enrollments in a study of its Virtue Sirolimus AngioInfusion ...
Stocktwits on MSN
Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care
Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company advancing ...
CalmWave, creator of the Calm ICU™ and leader in eliminating non-actionable alarms through healthcare data science and Transparent AI, today announced the launch of Alarm Insights, a new solution that ...
Orchestra BioMed’s Virtue® Sirolimus AngioInfusionTM Balloon (“Virtue SAB”) is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release ...
Orchestra BioMed enrols first patients in Virtue SAB pivotal investigational device exemption coronary trial: New Hope, Pennsylvania Wednesday, October 29, 2025, 18:00 Hrs [IST] O ...
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has begun enrolling patients in the Virtue SAB in the Treatment ...
WEST JEFFERSON, OH and GAITHERSBURG, MD / ACCESSWIRE / October 31, 2023 / AmplifyBio, a leading service provider for the commercialization of advanced modality therapeutics, and Vector BioMed, a ...
New agreement grants Terumo Virtue SAB coronary indication right of first refusal and supersedes prior distribution agreementTerumo to pay a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback